Product Description
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02772003)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Puerto Rico, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Communicable Diseases|Hepatitis A|Hepatitis C, Chronic|Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCI-2015-00558 | P1 |
Active, not recruiting |
Hepatocellular Carcinoma|Communicable Diseases|Hepatitis A|Hepatitis C, Chronic |
2020-03-04 |
50% |
2024-10-22 |
Recent News Events
Date |
Type |
Title |
|---|